“We are confident that we will be able to support ImmunogenX to optimize the production of its active ingredients," says Dr. Patrick Lorenz, VP Strategic Initiatives Bioscience at BRAIN Biotech. Lorenz is confident: "Patients affected by this widespread autoimmune disease will soon be able to benefit from this promising therapy, which may be first to market to address this significant unmet need in the gastrointestinal space.”
Dr. Jennifer Sealey Voyksner is CSO at ImmunogenX. She states: “We are excited to be able to utilize the expertise of BRAIN Biotech to ensure we use the most advanced technology for our manufacturing processes for IMGX003”.
Article published on June 17, 2021
